KKR will acquire Integer Holdings in an all-cash transaction valued at $5.7 billion including debt, paying $146 per share to shareholders of the medical-device contract manufacturer. The deal removes a $3.2 billion market-cap supplier to Medtronic, Abbott, and Boston Scientific from public markets and gives KKR control of 40 million cardiac rhythm management devices and 25 million neuromodulation components shipped annually.
Integer operates 19 manufacturing facilities across five countries, producing batteries, capacitors, and enclosures for implantable devices under long-term supply contracts. Revenue for the trailing twelve months ending September 2024 reached $1.48 billion with EBITDA margins near 22%, a profile that attracts private equity during periods when public medtech multiples compress but end-market procedure volumes remain stable. The transaction follows Integer's 2023 divestiture of its Electrochem power systems business to Currax, narrowing focus to the higher-margin cardio and neuro verticals where switching costs for OEM customers run into the hundreds of millions.
The move matters because it confirms private equity's thesis that contract development and manufacturing organizations in regulated sectors can be re-rated through operational leverage and bolt-on acquisitions away from quarterly earnings scrutiny. Integer's customer concentration—its top five clients represent 68% of revenue—creates downside protection in a take-private structure where KKR can negotiate multi-year volume commitments during the ownership transition. For the $87 billion medtech CDMO market, this deal establishes a reference price of roughly 8.5x EBITDA for established players with FDA-inspected cleanrooms and Design Control infrastructure, a multiple that will inform discussions around Integer's peers, including Nortech Systems and Plexus in the $500 million to $2 billion revenue band.
Allocators should track two follow-on events. First, whether KKR moves to acquire smaller medtech CDMOs in the next 12 to 18 months to build a rollup under Integer's compliance infrastructure, particularly firms with expertise in Class III active implantables where regulatory moats are widest. Second, whether Integer's existing OEM customers accelerate dual-sourcing initiatives before the deal closes in late 2025, a dynamic that could surface acquisition targets as smaller manufacturers gain RFQ volume they lack capacity to fulfill alone.
The transaction closes a $1.1 billion equity check from KKR at a moment when the firm's $19 billion Health Care Strategic Growth Fund II still holds $7.3 billion in dry powder, and procedural medtech margins are widening faster than device innovation is displacing incumbent suppliers.